# Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

> **NCT03486509** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 2 (estimated)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT03486509
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-01
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2018-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486509, "Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03486509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*